RIGEL PHARMACEUTICALS,INC. (NASDAQ:RIGL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e)
On January31, 2019, the Board of Directors of Rigel Pharmaceuticals,Inc. (the “Company”) approved the 2019 Cash Incentive Plan (the “Incentive Plan”), to which the Company’s named executive officers and other employees may become entitled to cash bonus payments based on attainment of specified corporate performance goals. A copy of the Incentive Plan is attached as Exhibit10.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
Description |
|
10.1 |
2019 Cash Incentive Plan |
RIGEL PHARMACEUTICALS INC Exhibit
EX-10.1 2 a19-3928_1ex10d1.htm EX-10.1 Exhibit 10.1 2019 CASH INCENTIVE PLAN Purpose: The terms of the 2019 Cash Incentive Plan (the “2019 Plan”) have been established to reward the executives and other employees of Rigel Pharmaceuticals,…
To view the full exhibit click here
About RIGEL PHARMACEUTICALS,INC. (NASDAQ:RIGL)
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company’s clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura (ITP); a Phase II clinical trial for autoimmune hemolytic anemia (AIHA), and a Phase II clinical trial for IgA nephropathy (IgAN). It has approximately two oncology product candidates in Phase I development. The Company is also engaged in conducting research in the disease areas of inflammation/immunology, and muscle wasting/muscle endurance, among others. Its product pipeline includes R348, which is a topical ophthalmic Janus kinase (JAK)/SYK inhibitor. The R348 product candidate is in Phase II clinical trials for the treatment of dry eye in patients with ocular graft-versus-host disease (GvHD).
